TXG 10x Genomics, Inc. - Common Stock

NAS · US · Healthcare · Medical Devices · 10xgenomics.com

93.50USD+5.34%Mkt Cap: 12.18B $P/E: —4d ago

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia P…

Industry Peers

Medical Devices

Screen all

ABT

Abbott Laboratories Common Stock

$169.83BUSDP/E 31.6

MDT

Medtronic plc. Ordinary Shares

$110.49BUSDP/E 21.2

SYK

Stryker Corporation Common Stock

$105.65BUSDP/E 28.5

BSX

Boston Scientific Corporation Common Stock

$61.74BUSDP/E 17.2

Edwards Lifesciences Corporation Common Stock

$49.03BUSDP/E 50.7

SHL

Siemens Healthineers AG

$46.06BUSDP/E 19.2

DXCM

DexCom, Inc. - Common Stock

$32.21BUSDP/E 33.7

GEHC

GE HealthCare Technologies Inc. - Common Stock

$29.24BUSDP/E 14.8

PHG

Koninklijke Philips N.V. NY Registry Shares

$23.38BUSDP/E 18.5

PHIA

Koninklijke Philips N.V.

$22.60BUSDP/E 18.7

STE

STERIS plc (Ireland) Ordinary Shares

Zimmer Biomet Holdings, Inc. Common Stock

$16.84BUSDP/E 21.4

PEN

Penumbra, Inc. Common Stock

$12.51BUSDP/E 77.8

SNN

Smith & Nephew SNATS, Inc. Common Stock

Globus Medical, Inc. Class A Common Stock

Bio-Rad Laboratories, Inc. Class A Common Stock

$9.88BUSDP/E 45.0

GKOS

Glaukos Corporation Common Stock

$9.66BUSD

Key Statistics

Company

Market Cap12.18B USD

Enterprise Value11.71B USD

Revenue (TTM)616.91M USD

Gross Profit443.88M USD

Net Income (TTM)-43.54M USD

Revenue/Share4.83 USD

Last Price93.50 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees1.2K

CountryUS

SectorHealthcare

IndustryMedical Devices

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)1219.51

PEG—

EV/EBITDA-284.19

EV/Revenue18.98

P/S19.75

P/B14.75

EPS (TTM)-0.59

EPS (Forward)0.08

52W Range

11.1698% of range95.16

52W High95.16 USD

52W Low11.16 USD

Profitability

Gross Margin69.05%

Oper. Margin-15.20%

EBITDA Margin-6.68%

Profit Margin-6.77%

ROE-5.47%

ROA-4.18%

Growth

Revenue Growth-12.70%

Earnings Growth—

Cash Flow & Leverage

Operating CF136.05M USD

CapEx (TTM)5.93M USD

FCF Margin29.12%

FCF Yield1.47%

Net Debt-473.24M USD

Net Debt/EBITDA11.49

Balance Sheet

Debt/Equity0.11

Current Ratio5.69

Quick Ratio5.08

Book Value/Sh6.34 USD

Cash/Share4.24 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating2.3 (Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)62.13 USD

Upside (mean)-33.5%

Target Range40.00 USD – 90.00 USD

40.00-33.5% to mean90.00

# Analysts15

Ownership

Shares Out.120.21M

Float118.19M

Insiders1.46%

Institutions120.29%

Short Interest

Short Ratio6.2d

Short % Float18.79%

Short % Out.12.81%

Shares Short16.69M

Short (prev mo.)15.93M

Technical

SMA 5064.80 (+44.3%)

SMA 20034.75 (+169.1%)

Beta2.08

S&P 52W Chg14.58%

Avg Vol (30d)3.02M

Avg Vol (10d)3.42M

Technical Indicators

RSI (14)79.2

MACD9.0641

MACD Signal7.9110

MACD Hist.+1.1531

BB Upper98.08 USD

BB Middle75.69 USD

BB Lower53.29 USD

BB Width59.18%

ATR (14)5.118 USD

Vol Ratio (20d)1.07x